XIV. Cerebral ischemia: The role of thrombosis and of antithrombotic therapy: Study group on antithrombotic therapy

Stroke

Volumn 8, Issue 1, 1977, Pages 150-175

  Genton, Edward ^a   Barnett, H J M ^b   Fields, William S ^c   Gent, Michael ^a   Hoak, John C ^d  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLASSIFICATION; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; MALE; THROMBOCYTE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ULTRASTRUCTURE;

AGED; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CEREBROVASCULAR DISORDERS; FEMALE; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMAN; INTRACRANIAL EMBOLISM AND THROMBOSIS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGE;

EID: 0017429139     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/01.STR.8.1.150     Document Type: Article

References (106)

1. Joint Committee for Stroke Facilities: I. Epidemiology for stroke facilities planning. Stroke 3: 360-371 (May-Jun) 1972
2. Kurtzke JF: Epidemiology of cerebrovascu lar disease. In Siekert RG (ed): Cerebrovascular Survey Report for Joint Council Subcommittee on Cerebrovascular Disease, National Institute of Neurological and Communicative Disorders and Stroke and National Heart and Lung Institute (revised). Rochester, Minnesota, Whiting Press Inc, pp 213-242, 1976
3. Cooper BS, Rice DP: The economic cost of illness revisited. Social Security Bulletin (Feb) 1976
4. Kurtzke JF: Epidemiology of Cerebrovascular Disease. New York, Springer-Verlag, 1969
5. Wolf PA: Hypertension as a risk factor for stroke. In Whisnant JP, Sandok BA (eds): Cerebral Vascular Diseases. Ninth Conference. New York, Grune and Stratton Inc, pp 105-112, 1974
6. Adams GF, Merrett JD, Hutchinson WM, et al: Cerebral embolism and mitral stenosis: Survival with and without anticoagulants. J Neurol Neurosurg Psychiat 37: 378-383 (Apr) 1974
7. Hernandez LM: Study of cerebral and peripheral emboli, registered in the National Institute of Cardiology of Mexico, from September, 1944, to May, 1946. Am Heart J 33: 712 (May) 1947
8. Harris AW, Levine SA: Cerebral embolism in mitral stenosis. Ann Intern Med 15: 637-643 (Oct) 1941
9. McDevitt E: Anticoagulant therapy in the treatment of cerebral thrombosis. In Wright I, Millikan C (eds): Cerebral Vascular Diseases. Second Conference. New York, Grune and Stratton Inc, pp 125-145, 1957
10. Szekely P: Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1: 1209-1212 (May 9) 1964
11. Keen G, Leveaux VM: Prognosis of cerebral embolism in rheumatic heart disease. Br Med J 2: 91-92 (Jul 12) 1958
12. Coulshed N, Epstein EJ, McKendrick CS, et al: Systemic embolism in mitral valve disease. Br Heart J 32: 26-34 (Jan) 1970
13. Carter AB: Prognosis of cerebral embolism. Lancet 2: 514-519 (Sep 11) 1965
14. Daley R, Mattingly TW, Holt CL, et al: Systemic arterial embolism in rheumatic heart disease. Am Heart J 42: 566-581 (Oct) 1951
15. Fleming HA, Bailey SM: Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med J 47: 599-604 (Sep) 1971
16. Owren PA: The results of anticoagulant therapy in Norway. Arch Intern Med 111: 240-247 (Feb) 1963
17. Browne TR III, Poskanzer DC: Treatment of strokes. N Engl J Med 281: 594-602 (Sep 11), 650-657 (Sep 18) 1969
18. Wright IS, Marple CD, Beck DF: Myocardial Infarction: Its Clinical Manifestations and Treatment with Anticoagulants. A Study of 1,031 Cases. New York, Grune and Stratton Inc, 1954
19. Millikan CH, Bauer RB, Goldschmidt J, et al: A classification and outline of cerebrovascular diseases II. Stroke 6: 564-616 (Sep-Oct) 1975
20. Fisher CM: Observations of the fundus oculi in transient monocular blindness. Neurology 9: 333-347 (May) 1959
21. Russell RWR: Observations on the retinal blood vessels in monocular blindness. Lancet 2: 1422-1428, 1961
22. Hollenhorst RW: Significance of bright plaques in the retinal arterioles. JAMA 178: 23-29 (Oct 7) 1961
23. Barnett HJM: Transient cerebral ischemia: Pathogenesis, prognosis and management. Ann R Coll Physicians Surg Can 7: 153-173, 1974
24. Hass WK, Fields WS, North RR, et al: Joint study of extracranial arterial occlusion. II. Arteriography, techniques, sites and complications. JAMA 203: 961-968 (Mar 11) 1968
25. Hass WK: Occlusive cerebrovascular disease. Med Clin North Am 56: 1281-1297 (Nov) 1972
26. Sanders WE: Undulant fever meningitis (organism in spinal fluid). J Iowa Med Soc 21: 510-511 (Sep) 1931
27. Barnett HJM, Hyland HH: Non-infective intracranial venous thrombosis. Brain 76: 36-49 (Mar) 1953
28. Canadian Collaboration Platelet-Inhibiting Drug Trial. Unpublished data
29. Reed RL, Siekert RG, Merideth J: Rarity of transient focal cerebral ischemia in cardiac dysrhythmia. JAMA 223: 893-895 (Feb 19) 1973
30. Brice JG, Dowsett DJ, Lowe RD: Haemodynamic effects of carotid artery stenosis. Br Med J 2: 1363-1366 (Nov 28) 1964
31. Romanul FCA, Abramowicz A: Changes in brain and pial vessels in arterial border zones. A study of 13 cases. Arch Neurol 11: 40-65 (Jul) 1964
32. Whisnant JP, Matsumoto N, Elveback LR: Transient cerebral ischemic attacks in a community. Mayo Clin Proc 48: 194-198 (Mar) 1973
33. Drake WE, Drake MAL: Clinical and angiographic correlates of cerebrovascular insufficiency. Am J Med 45: 253-270 (Aug) 1968
34. Millikan CH: Treatment of occlusive cerebrovascular disease. In Siekert RG (ed): Cerebrovascular Survey Report for Joint Council Subcommittee on Cerebrovascular Disease, National Institute of Neurological and Communicative Disorders and Stroke and National Heart and Lung Institute (revised). Rochester, Minnesota, Whiting Press Inc, pp 141-171, 1976
35. Friedman GD, Wilson WS, Mosier JM, et al: Transient ischemic attacks in a community. JAMA 210: 1428-1434 (Nov 24) 1969
36. Meyer JS, Guiraud B, Bauer R: Clinical and pathophysiological considerations of atherosclerotic and thrombotic disease of the carotid arteries. In Vinken PJ, Bruyn GW (eds): Vascular Diseases of the Nervous System. Handbook of Neurology. New York, American Elsevier Pub Co Inc, vol II, pp 327-365, 1972
37. Marshall J, Wilkinson IMS: The prognosis of carotid transient ischaemic attacks in patients with normal angiograms. Brain 94: 395-402, 1971
38. Marshall J, Meadows S: The natural history of amaurosis fugax. Brain 91: 419-434 (Sep) 1968
39. Marshall J: The natural history of transient ischaemic cerebrovascular attacks. Q J Med 33: 309-324 (Jul) 1964
40. Ziegler DK: Hypertensive vascular diseases of the brain. In Vinken PJ, Bruyn GW (eds): Vascular Diseases of the Nervous System. Handbook of Neurology. New York, American Elsevier Pub Co Inc, vol 11, pp 552-577, 1972
41. Millikan CH: Reassessment of anticoagulant therapy in various types of occlusive cerebrovascular disease. Stroke 2: 201-208 (Mar-Apr) 1971
42. Jones HR, Millikan CH: Temporal profile (clinical course) of acute carotid system cerebral infarction. Stroke 7: 64-71 (Jan-Feb) 1976
43. Carter AB: Anticoagulant treatment in progressing stroke. Br Med J 2: 70-73 (Jul 8) 1961
44. Millikan CH: The indications for various methods of treatment of occlusi ve ce rebrovascu lar disease. Trans Am Neurol Assoc 98: 206-218, 1973
45. Baker RN, Broward JA, Fang HC, et al: Anticoagulant therapy in cerebral infarction. Report on cooperative study. Neurology 12: 823-835 (Dec) 1962
46. Hass WK, Goldensohn ES: Clinical and electroencephalographic considerations in the diagnosis of carotid artery occlusion. Neurology 9: 575-589 (Sep) 1959
47. Fisher CM: Anticoagulant therapy in cerebral thrombosis and cerebral embolism: A national cooperative study, interim report. Neurology 11: 119-149 (Apr) 1961
48. Carter AB: Use of anticoagulants in patients with progressive cerebral infarction. Neurology 11: 601-609 (Jul) 1961
49. Harker LA, Slichter SJ: Platelets and fibrinogen consumption in man. N Engl J Med 287: 999-1005 (Nov 16) 1972
50. von Rokitansky C: Handbuch der Palhologischen Anatomie I Band. Handbuch der Allgemeinen Pathologischen Anatomic. Vienna, Braumuller und Seidel, p 510, 1842. Day GE (Eng trans) London, Sydenham Society, vol 4, p 261, 1852
51. Duguid JB: Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 58: 207-212 (Apr) 1946
52. Poole JCF, Sanders AG, Florey HW: The regeneration of aortic endothelium. J Pathol Bacteriol 75: 133-143 (Jan) 1958
53. Chandler AB, Hand RA: Phagocytized platelets: A source of lipids in human thrombi and atherosclerotic plaques. Science 134: 946-947 (Sep 29) 1961
54. Wu KK, Hoak JC: A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 2: 924-926 (Oct 19) 1974
55. Kalendovsky Z, Austin J, Steele P: Increased platelet aggregability in young patients with stroke. Diagnosis and therapy. Arch Neurol 32: 13-20 (Jan) 1975
56. Wu KK, Hoak JC: Increased platelet aggregates in patients with transient ischemic attacks. Stroke 6: 521-524 (Sep-Oct) 1975
57. Yin ET, Wessler S, Stoll PJ: Biological properties of the naturally occurring plasma inhibitor to activated factor X. J Biol Chem 246: 3703-3711 (Jun 10) 1971
58. Smith JB, Willis AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol) 231: 235-237 (Jun 23) 1971
59. Genton E, Gent M, Hirsh H, et al: Platelet-inhibiting drugs in the prevention of clinical thrombotic disease. N Engl J Med 293: 1174-1178 (Dec 4), 1236-1249 (Dec 11), 1296-1300 (Dec 18) 1975
60. Marquardsen J: The natural history of acute cerebrovascular disease: A retrospective study of 769 patients. Acta Neurol Scand 45 (Suppl 38): 9-188, 1969
61. Baker RN: An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease: Report of the Veterans Administration cooperative study of atherosclerosis. Neurology 11: 132-138 (Apr) 1961
62. Pearce JMS, Gubbay SS, Walton JN: Long-term anticoagulant therapy in transient cerebral ischaemic attacks. Lancet 1: 6-9 (Jan 2) 1965
63. Baker RN, Schwartz WS, Rose AS: Transient ischemie strokes. A report of a study of anticoagulant therapy. Neurology 16: 841-847 (Sep) 1966
64. Fisher CM: The use of anticoagulants in cerebral thrombosis. Neurology 8: 311-332 (May) 1958
65. Siekert RG, Whisnant JP, Millikan CH: Surgical and anticoagulant therapy of occlusive cerebrovascular disease. Ann Intern Med 58: 637-641 (Apr) 1963
66. Whisnant JP, Matsumoto N, Elveback LR: The effect of anticoagulant therapy on the prognosis of patients with transient cerebral ischemic attacks in a community. Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc 48: 844-848 (Dec) 1973
67. Marshall J, Reynolds EH: Withdrawal of anticoagulants from patients with transient ischaemic cerebrovascular attacks. Lancet 1: 5-6 (Jan 2) 1965
68. Millikan CH: Therapeutic agents — current status: Anticoagulant therapy in cerebrovascular disease. In Siekert RG, Whisnant JP (eds): Cerebral Vascular Diseases. Fourth Conference. New York, Grune and Stratton Inc, pp 181-184, 1965
69. Marshall J, Shaw DA: Anticoagulant therapy in acute cerebrovascular accidents. A controlled trial. Lancet 1: 995-998 (May 7) 1960
70. Hill AB, Marshall J, Shaw DA: Cerebrovascular disease: Trial of long-term anticoagulant therapy. Br Med J 2: 1003-1006 (Oct 20) 1962
71. Howard FA, Cohen P, Hickler RB, et al: Survival following stroke. JAMA 183: 921-925 (Mar 16) 1963
72. McDowell F, McDevitt E: Treatment of the completed stroke with long-term anticoagulant: Six and one-halfyears’ experience. In Siekert RG, Whisnant JP (eds): Cerebral Vascular Diseases. Fourth Conference. New York, Grune and Stratton Inc, pp 185-199, 1965
73. Enger E, Bjjyesen S: Long-term anticoagulant therapy in patients with cerebral infarction. A controlled clinical study. Acta Med Scand 178 (Suppl 438): 1-61, 1965
74. Howell DA, Tatlow WFT, Feldman S: Observations on anticoagulant therapy in thromboembolic disease of the brain. Can Med Assoc J 90: 611-614 (Mar 7) 1964
75. Thygesen P, Christensen E, Dyrbye M, et al: Cerebral apoplexy. A clinical, radiological, electroencephalographic and pathological study with special reference to the prognosis of cerebral infarction and the result of long-term am icoagula ti on therapy. Dan Med Bull 11: 233-257 (Dec) 1964
76. McDevitt E: Treatment of cerebral embolism. Mod Treat 2: 52-63 (Jan) 1965
77. Askey JJ, Cherry CB: Thromboembolism associated with auricular fibrillation. JAMA 144: 97-100 (Sep 9) 1950
78. Cosgrif TSW: Prophylaxis of recurrent embolism ofintracardiac origin. JAMA 143: 870-872 (Jul 8) 1950
79. Wells CE: Cerebral embolism. Arch Neurol Psych 81: 667-677 (Jun) 1959
80. Carter AB: Immediate treatment of cerebral infarction. Seven years’ personal experience. Lancet 1: 345-351 (Feb 13) 1960
81. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council: Assessment of short-term anticoagulant administration after cardiac infarction. Br Med J 1: 335-342 (Feb 8) 1969
82. Veterans Administration Hospital Investigators: Anticoagulants in acute myocardial infarction. Results of a cooperative clinical trial. JAMA 225: 724-729 (Aug 13) 1973
83. Harvald B, Hilden T, Lund E: Long-term anticoagulant therapy after myocardial infarction. Lancet 2: 627-630 (Sep 29) 1962
84. Sibley WA, Morledge JH, Lapham LW: Experimental cerebral infarction: The effect of dicumarol. Am J Med Sci 234: 661-663 (Dec) 1957
85. Moyes PD, Millikan CH, Wakim KG, et al: Influence of anticoagulants on experimental canine cerebral infarcts. Proc Staff Meet Mayo Clin 32: 124-130 (Mar 20) 1957
86. Whisnant JP, Millikan CH, Sayre GP, et al: Effect of anticoagulants on experimental cerebral infarction. Clinical implications. Circulation 20: 56-65 (Jul) 1959
87. Acheson J, Danta G, Hutchinson EC: Controlled trial of dipyridamole in cerebral vascular disease. Br Med J 1: 614-615 (Mar 8) 1969
88. Acheson J, Hutchinson EC: Controlled trials of clofibrate in cerebral vascular disease. Atherosclerosis 15: 177-183 (Mar-Apr) 1972
89. Evans G: Effect of platel et-sup pressi ve agents on the incidence of amaurosis fugax and transient cerebral ischemia. In McDowell FH, Brennan RW (eds): Cerebral Vascular Diseases. Eighth Conference. New York, Grune and Stratton Inc, pp 297-299, 1973
90. Gent M: Canadian cooperative study of recent recurrent presumed cerebral emboli (RRPCE). Design and organization of the study. In Hirsh J, Cade JF, Gallus AS, et al (eds): Platelets, Drugs and Thrombosis. Basel, Karger, pp 253-257, 1975
91. Blakely JA, Gent M: Platelets, drugs and longevity in a geriatric population. In Hirsh J, Cade JF, Gallus AS, et al (eds): Platelets, Drugs and Thrombosis. Basel, Karger, pp 284-291, 1975
92. Dyken ML, Kolar OJ, Jones FH: Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy. Stroke 4: 732-736 (Sep-Oct) 1973
93. Harrison MJG, Marshall J, Meadows JC, et al: Effect of aspirin in amaurosis fugax. Lancet 2: 743-744 (Oct 2) 1971
94. Mundall J, Quintero P, von Kaulla KN, et al: Transient monocular blindness and increased platelet aggregability treated with aspirin: A case report. Neurology 22: 280-285 (Mar)1972
95. Sullivan JM, Harken DE, Gorlin R: Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 284: 1391-1394, 1971
96. Gent M: Platelet inhibitor therapy in cerebrovascular disease. Thromb Diath Haemorrh (Suppl) 60: 509-516, 1974
97. Pechet L, Genton E: Fibrinolysis. In Mengel CE, Frei E, Nachman R (eds): Hematology — Principles and Practice. Chicago, Year Book Medical Publishers, pp 657-670, 1972
98. Atkin N, Nitzberg S, Dorsey J: Lysis of intracerebral thromboembolism with fibrinolysin. Report of a case. Angiology 15: 436-439 (Oct) 1964
99. Herndon RM, Meyer JS, Johnson JF, et al: Treatment of thrombosis with fibrinolysin. Preliminary report. Am J Cardiol 6: 540-545 (Aug) 1960
100. Schmutzler R, Koller F: Thrombolytic therapy. In Poller L (ed): Recent Advances in Blood Coagulation. Boston, Little Brown and Co, pp 299-335, 1969
101. Meyer JS, Herndon RM, Johnson TF, et al: Treatment of cerebrovascular thrombosis with plasmin and plasminogen activators. In Millikan CH (ed): Research Publications, Association for Research in Nervous and Mental Disease. Baltimore, Williams and Wilkins, vol 41, pp 373-398, 1966
102. Meyer JS, Gilroy J, Barnhart ME, et al: Therapeutic thrombolysis in cerebral thromboembolism: Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 13: 927-937 (Nov) 1963
103. Meyer JS, Gilroy J, Barnhart ME, et al: Therapeutic thrombolysis in cerebral thromboembolism: Randomized evaluation of intravenous streptokinase. In Siekert RG, Whisnant JP (eds): Cerebral Vascular Diseases. Fourth Conference. New York, Grune and Stratton Inc, pp 200-213, 1965
104. Hass WK, Clauss RH, Goldberg AF, et al: Special problems associated with surgical and thrombolytic treatment of strokes. Arch Surg 92: 27-31 (Jan) 1966
105. Fletcher AP, Alkjaersig N, Lewis M, et al: A pilot study of urokinase therapy in cerebral infarction. Stroke 7: 135-142 (Mar-Apr) 1976
106. Hanaway J, Torack R, Fletcher AP, et al: Int racra nial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 7: 143-146 (Mar-Apr) 1976